ID-119031166 is under clinical development by ILEAD Biomedical Science and currently in Phase I for Metabolic Dysfunction-Associated Steatohepatitis (MASH). According to GlobalData, Phase I drugs for Metabolic Dysfunction-Associated Steatohepatitis (MASH) does not have sufficient historical data to build an indication benchmark PTSR for Phase I. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the ID-119031166 LoA Report. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
ILEAD Biomedical Science overview
iLEAD Biomedical Science, a subsidiary of Ildong Pharmaceutical Co Ltd, engaged in research and development of novel drugs with focus in the area of small molecule medicinal chemistry for the treatment of various diseases. The company is headquartered in Hwaseong-si, Gyeonggi-do, South Korea.
For a complete picture of ID-119031166’s drug-specific PTSR and LoA scores, buy the report here.